** Shares of drugmaker MannKind rise 2.1% to $6.81 premarket
** MNKD and partner Cipla say the Central Drugs Standard Control Organisation (CDSCO) in India has approved MNKD's insulin inhalation powder Afrezza
** India has the second highest burden of diabetes worldwide the companies say
** MNKD expects to ship product for CIPL by end of 2025
** Under the agreement, CIPL is responsible for obtaining regulatory approvals to distribute Afrezza in India as well as marketing and sales activities, while MNKD is responsible for supplying it
** Up to last close, MNKD up 83.2% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。